// App-Quantinova.ai

2037 : Phase 1, multicenter, open-label, dose-escalation, study of marizomib (MRZ) and bevacizumab (BEV) in WHO grade IV malignant glioma (G4 MG).

Researchers

Presenter

  • Daniela Annenelie Bota

Principal Investigators

  • Annick Desjardins

  • Warren P. Mason

  • Howard Alan Fine

  • Steven D. Reich

  • Mohit Trikha

Medical Centers

  • UC Irvine Medical Center, Orange, CA

  • Duke University Medical Center, Durham, NC

  • Princess Margaret Hospital, Toronto, ON, Canada

  • New York University Medical Center, New York City, NY

  • Clinical Rsrch Consult, Del Mar, CA

  • Triphase Accelerator, San Diego, CA

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gliomas

Biomarkers

  • N/A

Drug/Treatment

  • Bevacizumab

  • Marizomib

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

  • Dose Escalation

Phase

  • I

Study Id's

  • NCT02330562

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved